Galapagos and AbbVie Present New Cystic Fibrosis Treatment Projects at ECFS Conference
Galapagos NV, a clinical-stage biotechnology company, recently delivered a joint presentation with AbbVie during the 38th annual conference of the European Cystic Fibrosis Society held in Brussels, Belgium. The presentation revealed co-developed technologies to address CF, part of Galapagos’ pipeline that includes three Phase 2 programs, two Phase 1 trials, five pre-clinical studies, and…